This was a brief introduction to OrbiMed and the trust. OrbiMed manage the trust and are the largest healthcare investor with a global reach. They invest $20 billion in a mix of public and private equity. The strategy has a US focus, but they are adding more into emerging markets with teams on the ground in India and China.
They believe this is a golden era for healthcare with more innovation, drugs, spending and patients. Innovations fall across cures, treatments, and technologies. And yet with so much positive news valuations remain at all time lows. Particularly in the US much of this seems to be focused on what Biden will do but they believe his focus will be the economy rather than attacking the healthcare sector.
Where this sits for investors is that it goes across the different opportunity sets and therefore allows the managers to seek the best opportunities. The current split is 33% in biotechnology, 23% in pharmaceutical, 18% in healthcare supplies, 16% in healthcare services, 7% in life sciences and the balance in other relevant areas….read more